TransThera Sciences (Nanjing). Inc.

As of December 31, 2025, TransThera Sciences (Nanjing). Inc. carries a market capitalization of 45.60B, placing it among publicly traded companies globally. Its enterprise value stands at 45.06B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, TransThera Sciences (Nanjing). Inc. has 396.90M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, TransThera Sciences (Nanjing). Inc. maintains a current ratio of 3.87, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

As of the close on October 22, 2026, TransThera Sciences (Nanjing). Inc.'s stock has declined approximately 95.55% over the past 52 weeks. The 50-day moving average sits at 10.00, while the 200-day moving average is 42.58.

As of December 31, 2025, TransThera Sciences (Nanjing). Inc. holds 544.36M in cash and equivalents against 1.83M in total debt, resulting in a net debt position of -462.30M. Total book value stands at 463.38M, with working capital of 413.24M providing operational flexibility.